Komori
TOKAI Corp. (9729) · InitiativeAdvanced

Improving operational efficiency and productivity through DX and creating new value

First written in FY2021. 7 of 11 entries say "Advanced", first in FY2022. Latest entry: FY2027-H1.

11entries
6years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2021AdvancedFY2023 – FY2027-H12021: 120212022: 320222023: 220232024: 020242025: 120252026: 42026
Same theme, other companies
Improving Pharmacy Operations and Healthcare Quality, Including AI and Capital InvestmentA theme 5 companies write about · 0 as a headwind · 6 as a tailwind

3 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2027-H1AdvancedAnnual report

    「We worked to enhance patient-facing services, including medication follow-up, through more efficient operations enabled by the introduction of AI medication records at all stores, while also strengthening our response to home healthcare and medical DX.」

    AI medication records have progressed from the previous stage of introduction and initial operation to a stage of improving operating efficiency through deployment at all locations. The system is being used to strengthen medication follow-up, home healthcare and the company’s response to medical DX.
  2. FY2026AdvancedAnnual report

    「We are also promoting productivity improvements through measures including the launch of an AI medication-history system, the centralization of medical administrative work, and remote medication guidance by pharmacists.」

    In addition to developing DX talent and implementing LINE mini-apps, the company has advanced to the stage of putting AI medication records, the centralization of medical administrative services and pharmacists’ remote medication guidance into actual operation.
  3. FY2026-H1AdvancedAnnual report

    「In terms of profit, despite higher costs against a backdrop of drug price revisions and tight pharmaceutical supplies, increased technical fee revenue, driven by stronger primary pharmacy functions and progress in obtaining medical DX promotion system preparation surcharges, contributed to higher profit than in the previous interim consolidated accounting period.」

    The company states that progress in obtaining the medical DX promotion system enhancement add-on in the dispensing pharmacy business contributed to higher technical service revenue. In addition to DX talent development and individual implementations, the establishment of systems under the medical fee schedule was identified as contributing to results.
  4. FY2023AdvancedAnnual report

    「With regard to DX, which is positioned as essential to sustainable corporate growth, we have promoted company-wide initiatives centered on developing DX personnel based on the "Tokai Group DX Medium-term Strategy" formulated in May 2022, while also focusing on individual initiatives in each business, such as improving patient convenience through a LINE mini app in the dispensing pharmacy business and improving efficiency by digitizing various procedures in the Silver business.」

    In addition to developing talent based on the DX medium-term strategy, the company has newly specified concrete implementation examples in each business, including a LINE mini-app for dispensing pharmacies and the digitization of procedures in the silver services business.
  5. FY2023-Q3RestatedAnnual report

    「Regarding DX, which we regard as essential to sustainable corporate growth, we are focusing on developing DX talent based on the "Tokai Group DX Medium-Term Strategy" announced in May. We will continue working to foster an organizational culture that actively takes on the challenges of resolving issues and enhancing added value in each business and creating new businesses through DX, while promoting various initiatives.」

    The company continues to develop DX talent based on the DX medium-term strategy and pursue initiatives to resolve issues, enhance added value and create new businesses in each business.
  6. FY2023-Q2AdvancedAnnual report

    「Under the medium-term management plan “Challenge for the new stage!”, which covers the period through the fiscal year ending March 2025, the Company positions DX as essential to sustainable corporate growth. Based on the “トーカイ Group DX Medium-Term Strategy” announced in May, it began offering e-learning courses for all employees in June and courses for selected DX promoters in July, focusing on the development of DX personnel. The Company will continue working to foster a corporate culture that actively takes on the challenge of resolving issues in each business, enhancing added value, and creating new businesses through DX, while promoting related initiatives.」

    Based on the DX medium-term strategy announced in May, the company began offering courses for all employees in June and for selected DX leaders in July. It is moving DX talent development into the concrete execution stage.
  7. FY2023-Q1AdvancedAnnual report

    「Regarding DX initiatives, which are essential to sustainable corporate growth, we announced the "Tokai Group DX Medium-Term Strategy" in May with the aim of promoting the digital strategy across the group and establishing a group-wide DX foundation. From June, we launched an in-house training program to develop DX talent and are working to foster an organizational culture that actively takes on the challenges of resolving issues and enhancing added value in each business and creating new businesses through DX, as well as to build a group-wide foundation for implementing various initiatives.」

    Following the announcement in May of the "Tokai Group DX Medium-Term Strategy," the company launched an in-house training program to develop DX talent in June. It is moving into the concrete execution stage for resolving issues through DX, enhancing added value, creating new businesses and building a group-wide foundation.
  8. FY2022AdvancedAnnual report

    「DX is positioned as one of the key initiatives. To clarify the direction of future initiatives, the company formulated the "Tokai Group DX Medium-term Strategy" in May 2022.」

    Regarding the DX outlined in the medium-term management plan, the company formulated the group’s medium-term strategy in May 2022 and is moving into a stage in which employees proactively use digital technologies to drive initiatives across the group.
  9. FY2021First statedAnnual report

    「"Improving operational efficiency and productivity through DX" and "Creating new business models through DX"」

    As measures under the medium-term management plan to "change" and "create," the company has specified for the first time the use of DX to improve the efficiency and productivity of existing operations and create new business models.
Moved together

"Balancing Growth Investment with Stable Dividends" moved the same way as this thread, in the same document, in 6 of its 11 moves.

665544★123456
  1. ★This thread
  2. 1Balancing Growth Investment with Stable Dividends6×
  3. 2Core-segment revenue growth and record-high results6×
  4. 3Pharmacy Store Expansion and Response to Community Healthcare Needs5×
  5. 4Capital investment in new factories, laundry facilities and other equipment5×
  6. 5Responding to integrated community care through collaboration across the Group and its businesses4×
  7. 6Business Expansion Through M&A4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for TOKAI Corp. yet. It last moved in the Financial results presentation of 2026-11-12: "Mitigated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.